Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

AbbVie’s Humira loss of exclusivity a missed opportunity for competitors, says GlobalData

AbbVie‘s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. Despite an anticipated competitive surge, rivals have struggled to capitalize. AbbVie’s strategic shift to Skyrizi (risankizumab) and Rinvoq (upadacitinib) has solidified its position, underscoring a missed opportunity for competitors in the immunology […]
Read more

Roche’s foray into continuous glucose monitors dependent on AI efficacy, says GlobalData

Roche’s artificial intelligence (AI)-enabled continuous glucose monitoring system has gained Conformité Européenne (CE) marking. If this AI tool can accurately predict glucose levels, this new tool has the potential to provide diabetic patients with a greater degree of control and prevent dangerous hypo- and hyperglycemic events. However, the system’s success hinges on the accuracy and […]
Read more

US-China tech dynamics shine light on thriving underwater drone investments, notes GlobalData

In a race to strengthen underwater capabilities, the US and China are accelerating efforts in advanced technologies such as the Manta Ray underwater drone, highlighting their strategic significance. The recent developments highlight the critical role of underwater drones in military, environmental, and infrastructure applications. With significant investments driving innovation in endurance, navigation, and data collection […]
Read more

Diagnosed prevalent cases of chronic kidney disease to reach 22.97 million across 7MM in 2033, predicts GlobalData

The diagnosed prevalent cases of chronic kidney disease (CKD) across the seven major markets (*7MM) are projected to increase at an annual growth rate (AGR) of 0.90% from 21.08 million in 2023 to 22.97 million in 2033, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Chronic Kidney Disease: Epidemiology Forecast to 2033,” […]
Read more

GenAI to revolutionize financial services with enhanced decision-making and personalization, says GlobalData

Generative AI (genAI) is set to transform financial services across banking, insurance, and wealth management. This technology is advancing through distinct phases, offering transformative capabilities such as enhanced decision-making, personalized services, and innovative product development. With significant funding growth and increasing adoption, genAI is set to drive unprecedented innovation and operational efficiency in the industry, […]
Read more

AI and robotics unlock sustainable efficiency in oil and gas sector, says GlobalData

Artificial intelligence (AI) and robotics are leading the transformative changes in the oil and gas sector, accelerating advancements in operational efficiency, safety, and environmental sustainability. These technologies are reshaping how the sector approaches exploration, production, refining, and logistics, instituting a new era of innovations for heightened productivity, efficiency, sustainability, and safety, according to GlobalData, a […]
Read more

Ajovy benefits diminish with migraine treatment cessation and re-initiation, says GlobalData

The interim results from the observational, prospective Phase IV Pan-European Real-Life (PEARL) study, presented at the 10th Congress of the European Academy of Neurology, indicate that treatment cessation and re-initiation can reduce the benefits of Teva Pharmaceutical’s Ajovy for migraine management. Continuous administration of Ajovy is crucial for effective prevention, challenging current guidelines that recommend […]
Read more

VNS and cenobamate combo therapy success paves way for cenobamate monotherapy, says GlobalData

At the recently held 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of a new anti-seizure medication (ASM), Xcopri (cenobamate) and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy demonstrated significant improvements in seizure control, highlighting its potential […]
Read more

Precision medicine transforms healthcare beyond oncology, says GlobalData

Precision medicine is reshaping healthcare beyond its traditional focus on oncology. This innovative approach tailors medical treatments to individual genetic, environmental, and lifestyle factors, enhancing disease prevention, diagnosis, and treatment efficacy. From reproductive health advancements like biomarker screenings in IVF to pandemic preparedness initiatives, precision medicine is expanding its impact across diverse medical fields, promising […]
Read more

AI-augmented robotics to elevate Industry 4.0, says GlobalData

The integration of advanced robotics and artificial intelligence (AI) is transforming several industries such as manufacturing, healthcare, automotive, and aerospace and forging a path towards the realization of Industry 4.0. While companies are heavily investing in proprietary technologies for innovation and productivity, challenges like cybersecurity and high costs remain. Collaborative R&D efforts and standardized policies […]
Read more

EMA approval of Sanofi/Regeneron’s Dupixent fills biologic gap in COPD, says GlobalData

Following the European Medicines Agency (EMA) approval of Sanofi/Regeneron’s Dupixent (Dupilumab) on 03 July 2024: Asiyah Nawab, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent, a monoclonal antibody (mAb) targeting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, has been approved by the EMA as the first biologic for uncontrolled chronic […]
Read more
1 … 55 56 57 58 59 … 206